Effect of RFs accumulation on HBI0101 outcome and impact of treatment lines on RFs acquisition. (A-C) Best ORR (A), PFS (B), and OS (C) were estimated in patients receiving HBI0101 infusion, according to their acquisition of RFs, with RF = 0 defined as no RF (red lines); RF = 1 defined as 1 RF (that is, RF HR cytogenetic or extramedullary presentation or the absolute number of CAR⁺ T_EMs detected in HBI0101 FP; blue lines), RF = 2/3, defined as acquisition of 2 or 3 RFs of the formers (green lines). (D-F) Effect of the number of treatment lines endured by patients with myeloma on the acquisition of HR cytogenetic (D), EMD (E), and on the number of CAR⁺ T_EMs in the FP (F). In panel 4A, the percentages for CR, VGPR, and PR do not add up to the percentage atop the bar graph due to rounding.